This study is called the PlaComOv-study. It is an acronym for ‘Will the use of the PLAsmajet device improve the rate of COMplete cytoreductive surgery for advanced stage OVarian cancer.
In this study, 330 patients with a FIGO IIIB-IV epithelial ovarian cancer, carcinoma of the fallopian tube or extra-ovarian epithelial ovarian cancer(peritoneal cancer) in whom the surgical goal is to achieve complete cytoreduction will be included. Patients should to be fit for CCS and chemotherapy.
Patients from the following Dutch hospitals may be included: Albert Schweitzer (Dordrecht), Bravis (Bergen op Zoom), Catharina Cancer Institute (Eindhoven), Erasmus MC (Rotterdam), Franciscus Gasthuis and Vlietland (Rotterdam), Groene Hart Hospital (Gouda), Haags Medisch Centrum (Den Haag), Haga Hospital (Den Haag), Leids University MC (Leiden), Medisch Spectrum Twente (Enschede), Reinier de Graaf Groep (Delft).
All surgeons are trained and certified in the use of PlasmaJet during the preparation of the study.
This study will compare the complete cytoreductive surgery rate when using electrocoagulation only (standard) with that achieved with additional use of the PlasmaJet Surgical Device (intervention). We expect that use of the PlasmaJet during surgery will result in a higher rate of complete cytoreduction and fewer colostomies [14 –20 (link)].
Standard therapy is primary cytoreductive (upfront) surgery followed by chemotherapy, or neoadjuvant chemotherapy followed by interval cytoreductive surgery. Standard chemotherapy comprises of 6 cycles of carboplatin and paclitaxel, with a duration of 21 days for each cycle [1 ]. In upfront cytoreductive surgery, all 6 cycles of chemotherapy are given after surgery. In interval cytoreductive surgery, 3 cycles of chemotherapy are administered prior to surgery and 3 cycles thereafter. Patients from both the upfront and interval cytoreductive groups may be included.
The standard of care is to reach complete cytoreduction in all women who are fit to undergo extensive surgery. This radical surgery may involve bowel surgery sometimes including colostomy. Electrocoagulation (Diathermy, LigaSure), scalpel and scissors are used during conventional surgery to remove visible tumour and to dissect tumour tissue from peritoneal surfaces. The disadvantage of electrocoagulation is the lateral thermal spread and the depth of tissue destruction, which render it unsuitable for use on the intestines. Electrocoagulation (Diathermy, LigaSure), scalpel, scissors and PlasmaJet are used when indicated during surgery in the intervention arm.
In this study, 330 patients with a FIGO IIIB-IV epithelial ovarian cancer, carcinoma of the fallopian tube or extra-ovarian epithelial ovarian cancer(peritoneal cancer) in whom the surgical goal is to achieve complete cytoreduction will be included. Patients should to be fit for CCS and chemotherapy.
Patients from the following Dutch hospitals may be included: Albert Schweitzer (Dordrecht), Bravis (Bergen op Zoom), Catharina Cancer Institute (Eindhoven), Erasmus MC (Rotterdam), Franciscus Gasthuis and Vlietland (Rotterdam), Groene Hart Hospital (Gouda), Haags Medisch Centrum (Den Haag), Haga Hospital (Den Haag), Leids University MC (Leiden), Medisch Spectrum Twente (Enschede), Reinier de Graaf Groep (Delft).
All surgeons are trained and certified in the use of PlasmaJet during the preparation of the study.
This study will compare the complete cytoreductive surgery rate when using electrocoagulation only (standard) with that achieved with additional use of the PlasmaJet Surgical Device (intervention). We expect that use of the PlasmaJet during surgery will result in a higher rate of complete cytoreduction and fewer colostomies [14 –20 (link)].
Standard therapy is primary cytoreductive (upfront) surgery followed by chemotherapy, or neoadjuvant chemotherapy followed by interval cytoreductive surgery. Standard chemotherapy comprises of 6 cycles of carboplatin and paclitaxel, with a duration of 21 days for each cycle [1 ]. In upfront cytoreductive surgery, all 6 cycles of chemotherapy are given after surgery. In interval cytoreductive surgery, 3 cycles of chemotherapy are administered prior to surgery and 3 cycles thereafter. Patients from both the upfront and interval cytoreductive groups may be included.
The standard of care is to reach complete cytoreduction in all women who are fit to undergo extensive surgery. This radical surgery may involve bowel surgery sometimes including colostomy. Electrocoagulation (Diathermy, LigaSure), scalpel and scissors are used during conventional surgery to remove visible tumour and to dissect tumour tissue from peritoneal surfaces. The disadvantage of electrocoagulation is the lateral thermal spread and the depth of tissue destruction, which render it unsuitable for use on the intestines. Electrocoagulation (Diathermy, LigaSure), scalpel, scissors and PlasmaJet are used when indicated during surgery in the intervention arm.
Full text: Click here